Last reviewed · How we verify
Anti-CD22 CAR NK Cells
Targeting CD22 on B cells
Targeting CD22 on B cells Used for B-cell malignancies.
At a glance
| Generic name | Anti-CD22 CAR NK Cells |
|---|---|
| Sponsor | Allife Medical Science and Technology Co., Ltd. |
| Drug class | CAR T-cell therapy |
| Target | CD22 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Anti-CD22 CAR NK Cells are a type of immunotherapy that uses genetically modified natural killer cells to target and destroy cancer cells expressing CD22.
Approved indications
- B-cell malignancies
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CD22 CAR NK Cells CI brief — competitive landscape report
- Anti-CD22 CAR NK Cells updates RSS · CI watch RSS
- Allife Medical Science and Technology Co., Ltd. portfolio CI